Cancer Chemotherapy and Pharmacology Oncology

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity

Nuala Helsby, Katrina Sharples, Yu Jin Kim, David Porter, Kathryn Burns, Soo Hee Jeong, Sarah Benge, Sanjeev Deva, Ben Lawrence, Christopher Jackson, Richard North, R. Matthew Strother, John Duley, Michael Findlay
Springer Nature · 2025-08-18 · DOI 10.1007/s00280-025-04804-6

Abstract

Abstract Purpose Inherited dihydropyrimidine dehydrogenase (DPD) deficiency is a risk factor for severe 5-fluorouracil toxicity. We report a phenotyping approach (thymine challenge test) to prospectively determine DPD activity and the association with severe adverse events. Methods The primary aim of this prospective study was to determine whether a thymine challenge test could prospectively identify patients at risk of severe toxicity from treatment with 5-fluorouracil/capecitabine in combination chemotherapy schedules or monotherapy. The focus was prediction of those at risk of ≥ grade 3 gastrointestinal toxicity. DPD activity was determined from the thymine/dihydrothymine (THY/DHT) ratio measured in a urine sample after a thymine test dose (250 mg, oral). Results Of the 166 patients, 11.7% had severe diarrhoea/mucositis. The THY/DHT ratio was not significantly different in these individuals compared to those with minimal toxicity. However, post hoc analysis found decreased DPD activity in those who had non-gastrointestinal toxicity, most notably grade ≥ 2 Hand-Foot syndrome ( p = 0.001). Conclusion The data do not support our primary hypothesis that this phenotyping approach would discriminate those at risk of severe/life-threatening gastrointestinal toxicity. The clinical factors which influence gastrointestinal toxicity, particularly in patients receiving CAPOX require further investigation. Clinical trial registration ACTRN 12,617,001,109,392 registered 28/07/2017.

Read at publisher →